Detailed instructions for tissue collection, processing and shipment are provided in the Laboratory Manual. s An optional CT or an ultrasound- guided core needle biopsy should be performed at the site presented for mesothelioma for consenting subjects . t A 7-day course of antibiotics will be taken starting 7 days after the 2nd dose of CRS- 207 (PV2) and after final dose of CRS- 207 when treatment is discontinued. A 7-day course of antibiotics will be initiated at the EOS visit after blood has been collected for CRS- 207 culture. Antibiotic regimens must be completed prior to initiation of any other cancer -related therapy. Subjects with a central line port will receive 1 dose of IV antibiotics followed by 6 days of oral antibiotics; all other subjects will receive 7 days of oral antibiotics (refer to Section 5.2.2.5). Site personnel will contact the subject by telephone to facilitate compliance with antibiotic treat ment; subjects required to record self -administration of antibiotics in a diary. u Subjects who are clinically stable and meet dosing eligibility, will continue to receive maintenance vaccinations beginning at the first follow -up visit 4 weeks after EOC and every 8 weeks thereafter . Subjects may continue on treatment with radiographic disease progression if they are clinically stable and the Investigator believes the treatment may be providing benefit . A 7-day course of antibiotics starting 7 days after vaccination will be administered following the second dose of CRS- 207 (PV2) and after final dose of CRS- 207. v Blood for CRS- 207 culture will be collected at EOS to assess clearance of CRS- 207. At EOS , blood will be collected prior to initiation of antibiotics (if applicable, blood should also be collected from the central line port). w CRS-207 will be administered via i.v. injection ( 1 × 109 CFU in approximately 100 mL 0.9% sodium chloride) . Vital signs (BP, pulse, respiratory rate, temperature) will be measured every 30 minutes during the CRS-207 infusion and every hour during post -infusion follow -up. Subjects will be observed for at least 2 hours after each infusion. Subjects who are not stable enough to be released at 2 hours after infusion should continue to be monitored until subject is considered clinically stable. x CRS-207 premedications include the following: 650 mg of acetaminophen to be administered orally prior to each dose of CRS- 207. Subjects will receive a minimum of 500 mL of normal saline immediately before CRS- 207 infusion and at least 500 mL after infusion. Additional fluids may be given for persistent tachycardia, fever or hypotension based on investigator’s discretion. y Subjects may receive folic acid, cyanocobalamin, and anti -emetics premedication for chemotherapy per standard of care and investigator ’s practice . z The recommended dose of pemetrexed is 500 mg/m2 BSA in 100 mL 0.9% sodium chloride administered over 10 minutes as an i.v. infusion on Day 1 of 21 -day cycle. The recommended dose of cisplatin is 75 mg/m2 BSA in 1 L 0.9% sodium chloride with mannitol 30 g/L infused over 2 hours beginning approximately 30 minutes after end of pemetrexed administration on day 1 of 21- day cycle. Dose reductions may be required for subjects with hepatic or renal impairment or history of toxicity to pemetrexed or cisplatin. If a subject is determined to be intolerant to cisplatin after at least one dose, carboplatin may be substituted to be administered with pemetrexed per standard of care with the approval of the Sponsor . Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 32 Abbreviations: AE = adverse event; ALT = alanine aminotransferase; ANC = absolute neutrophil count; APTT = activated partial thromboplastin time; AST = aspartate aminotransferase; BUN = blood urea nitrogen; BV = boost vaccine; CBC = complete blood count; CT =computed tomography; EOS = End of Study; FDG -PET = positron emission tomography with fluorodeoxyglucose; FEV1 = forced expiratory volume in 1 second; HIV = human immunodeficiency virus; HLA = human leukocyte antigen; LDH = lactate dehydrogenase; Lm = Listeria monocytogenes; MRI = magnetic resonance imaging; PBMC = peripheral blood mononuclear cells ; PD = progressive disease; i.v. = intravenous; p.o.